News
Issues ranging from medicine approval delays to attacks on Harvard research grants knock driver of regional economy ...
An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...
Three simultaneous withdrawals—from the World Health Organization, USAID and the Gavi vaccine alliance—represent a ...
Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more
Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...
4d
The chamber stood idle for more than seven hours as GOP lawmakers met with President Trump and others shuttled in and out of ...
6d
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
The Trump administration is continuing to make its imprint on U.S. vaccine policy in recent days. The moves could change what ...
StockStory.org on MSN11d
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per ...
Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
It is big and it is beautiful, says President Donald Trump. But for many Democratic leaders, the tax break and spending cut ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback